The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.05 (1.52%)
Spread: 0.10 (3.03%)
Open: 3.30
High: 3.35
Low: 3.30
Prev. Close: 3.30
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: US Stocks Seen Mixed As Tech Giants Report

Tue, 21st Jul 2015 11:08

LONDON (Alliance News) - UK stocks are higher midday Tuesday as sentiment is being driven by company news and the movement in gold prices, while Wall Street is called for a mixed open ahead of the release of results from several US technology giants.

The FTSE 100 is up 0.2% at 6,798.97 points, the FTSE 250 is up 0.2% at 17,816.81, and the AIM All-Share is up 0.1% at 759.10. European major indices also are higher, with the CAC 40 in Paris up 0.2%, and the DAX 30 in Frankfurt up 0.1%.

US futures point to a mixed open, with the DJIA pointed down 0.1%, the S&P 500 flat, and the Nasdaq 100 up 0.2%. The Nasdaq Composite reached Monday a new record closing high at 5,218.85 points.

US technology stocks Apple, Microsoft or Yahoo are set to report results on Tuesday after the US market close, following IBM, which reported results Monday after the market close.

IBM said that its second quarter profit fell 17% from last year, as revenue declined 13.5%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. At the same time, IBM maintained its full year operating earnings outlook. The company now expects a modest increase in free cash flow, improved from its prior expectation of flat.

Gold is slightly higher on the day Tuesday at USD1,106.41 per ounce. The price of gold has recovered after slumping Monday morning to USD1,073.40 an ounce, a level it hasn't seen since early 2010. The precious metal traded at USD1,144.17 an ounce on Friday before its recent sell-off.

The decline in the gold has come amid speculation that the Federal Reserve will hike US interest rates as soon as September. Fed Chair Janet Yellen told Congress last week that the economy is improving at a pace that should allow the US central bank to begin normalizing rates by the year's end.

Kit Juckes, analyst at Societe Generale, says,"September and December Fed Funds futures are moving higher (in rate terms), with a third-quarter (ie, Sept) hike seen now as a distinct possibility again, and a fourth quarter hike as a strong probability."

The US dollar strengthened against most major currencies on Tuesday morning, in response to comments by St. Louis Federal Reserve President James Bullard that there is more than a 50% chance for a Fed rate hike in September.

"I see September having a 50% probability right now" for a boost in the Fed's overnight short-term interest rate target, Bullard told Fox Business Network. "The economy is much closer to normal today than it's been in quite a while, certainly over the last five years," he added.

The pound has recovered some of the ground gained by the dollar and is now flat at USD1.5555.

London-listed miners were hit Monday by the slump in gold prices. On Tuesday, the stocks are rebounding, with Fresnillo up 3.3%, Randgold Resources up 2.1%, Antofagasta up 0.9%, and BHP Billiton up 0.7%. In the FTSE 250, KAZ Minerals is up 2.7% and Acacia Mining is up 1.9%.

Outside miners, general insurers Admiral Group, up 3.5%, and RSA Insurance Group, up 1.5%, are higher after roadside assistance company AA found that car and home insurance premiums are set to rise due to an upcoming increase in the UK's insurance premium tax. AA said it thinks premiums may rise due to the decision by the UK government to increase the standard rate of insurance premium tax to 9.5% from 6%.

AO World is the biggest gainer in the FTSE 250, up 9.7%, after it said it is on track with its long-term strategic process as it continues to build brand awareness and plans to expand its services in Europe.

The online domestic appliances retailer said that sales continue to "build satisfactorily" in Germany, where it has entered into a ten-year lease for a new European distribution facility in Bergheim near Cologne, expecting to take occupation during the first half of the financial year 2017. The property will replace two of its existing sites and will facilitate expansion into countries surrounding Germany, the company said.

In the UK, AO World said revenue grew 6.5% in the three months to June 30, with orders up 13.9%, while AO.com experienced revenue growth of 11.2%. It said it had a strong start to trading in July and is encouraged by the indications of growth in housing transactions and disposable income in the broader market.

In the AIM All-Share index, ValiRx is up 23% after the life sciences company provided a positive update on the ongoing phase I/II dose escalation clinical trial of its cancer drug VAL201. The company said that over the last month the trial has continued to demonstrate safety and tolerability and no significant adverse effects have been recorded. The next dose escalation has been approved as a result of safety and tolerability data, which ValiRx said "may prove sufficient to show anti-tumour activity."

Meanwhile, Versarien is up 12%. The advanced engineering materials company posted a widened pretax loss for its recently ended financial year as higher costs offset strong growth in revenue, but expressed optimism for its current year. The company reported a pretax loss of GBP866,000 for the year to end-March, widened from a pretax loss of GBP653,000 a year before, as a rise in revenue to GBP5.0 million from GBP3.0 million was offset by a rise in operating expenses and exceptional costs of GBP307,000.

Nasstar is down 13%. The cloud computing services company said that while its first half trading in 2015 was in line with its expectations, it now expects to miss its forecasts for the full year due to a series of challenges set to hit the business in the second half. Among those challenges, a key client is consolidated its IT services in the second half and the group is set to lose licensing revenue from another client.

In economic news, UK public sector net borrowing decreased in June from last year, the Office for National Statistics said. Excluding public sector banks, PSNB dropped GBP0.8 billion to GBP9.4 billion in June. It was equivalent to 0.5% of gross domestic product. The decline in net borrowing was resulted from an increase of GBP0.1 billion in central government net borrowing being more than offset by a decrease of GBP1 billion in local government net borrowing.

Still in a very light economic calendar Tuesday is the US Redbook index, due at 1355 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
21 Mar 2024 11:22

ValiRx inks evaluation deal with Imperial College London for research

(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeutic candidates for cancer treatment.

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Feb 2024 14:45

ValiRx says requisition notice from shareholder group is invalid

(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following legal advice.

Read more
12 Feb 2024 12:59

ValiRx inks deal with Dundee Drug Discovery Unit

(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.

Read more
12 Feb 2024 11:42

IN BRIEF: ValiRx signs research sharing deal with Dundee University

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug discovery unit to access research concerning novel therapeutic candidates. The agreement will be active for a period of five years, in which ValiRx may review research projects from the unit in areas aligned with the company's focus on cancer therapeutics.

Read more
9 Feb 2024 20:24

TRADING UPDATES: ValiRx receives shareholder request for board change

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Dec 2023 15:56

UK shareholder meetings calendar - next 7 days

Friday 29 December 
Apollon Formularies PLCAGM
Eco Atlantic Oil & Gas LtdAGM
Genedrive PLCAGM
Goldplat PLCAGM
Lansdowne Oil & Gas PLCGM re capital raise
Marula Mining PLCAGM
Microsaic Systems PLCGM re fundraise
Online Blockchain PLCAGM
Secure Property Development & Investment PLCAGM
SkinBioTherapeutics PLCAGM
Tetragon Financial Group LtdAGM
Woodbois LtdAGM
Zambeef Products PLCAGM
Monday 1 January 
no events scheduled 
Tuesday 2 January 
no events scheduled 
Wednesday 3 January 
Jubilee Metals Group PLCGM re equity raise
Thursday 4 January 
Rotala PLCGM re management buyout
Tintra PLCGM re cancellation, re-registering as private company
ValiRx PLCGM re operational review
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
19 Dec 2023 20:46

IN BRIEF: ValiRx raises GBP192,200, part of wider GBP1.8 million raise

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Says 3.2 million new shares have been subscribed for at 6 pence per share via a retail offer, raising GBP192,244. Also issues 499,998 new shares via a subscription. In total, raises GBP1.8 million via placing, subscription and retail offer of 30.0 million new shares.

Read more
13 Dec 2023 21:14

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Dec 2023 15:08

ValiRx enters option deal with Ambrose Healthcare

(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private UK-based pharmaceutical company.

Read more
5 Dec 2023 11:17

ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose

(Alliance News) - ValiRx PLC on Tuesday said that ValiSeek Ltd it has entered a deal to licence VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.

Read more
5 Dec 2023 10:59

AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
10 Nov 2023 11:49

ValiRx signs deal to evaluate StingRay Bio drug candidates

(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates.

Read more
10 Nov 2023 10:32

ValiRx enters partnership with StingRay Bio

(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.

Read more
6 Oct 2023 11:35

ValiRx sees no reason for shares jump; notes TheoremRx mulls merger

(Alliance News) - ValiRx PLC on Friday said it had no unpublished information that was sensitive to its share price, as it rose significantly.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.